Nectin Therapeutics
Nectin Therapeutics54
About
What does Nectin Therapeutics do?
Nectin Therapeutics develops immuno-oncology and ADC breakthrough therapies to overcome tumor escape and resistance mechanisms. Their diverse pipeline includes novel immuno-oncology antibodies and ADCs, with an anti-PVR asset currently in Phase 1 clinical trials. They aim to address difficult-to-treat cancers for patients who do not respond to approved immuno-oncology therapies.
What is Nectin Therapeutics's revenue?
StartupHub estimates Nectin Therapeutics's annual revenue at $1.9M (range $1.0M to $3.0M, 64% confidence), based on comparable companies in the sector.
What is Nectin Therapeutics's valuation?
StartupHub estimates Nectin Therapeutics's effective valuation at $261.5M (range $160.3M to $384.6M, 14% confidence), based on comparable companies in the sector.
How much funding has Nectin Therapeutics raised?
Nectin Therapeutics has raised a total of $64M in funding. The most recent round on record is Series C.
When was Nectin Therapeutics founded?
Nectin Therapeutics was founded in 2016.
What industry does Nectin Therapeutics operate in?
Nectin Therapeutics operates in Life Sciences, Immunotherapy, Immunology, Cancer, Cancer Immunotherapy, Antibody.
How many employees does Nectin Therapeutics have?
Nectin Therapeutics has approximately 11 people on record.
No comments yet. Be the first to share your take.